Celgene

Bristol-Myers Squibb And Celgene's Big Winner? Los Angeles Billionaire Patrick Soon-Shiong
Bristol-Myers Squibb And Celgene's Big Winner? Los Angeles Billionaire Patrick Soon-Shiong
Forbes
Patrick Soon-Shiong
Bristol-Myers Squibb
Celgene
M&A
Flag link:
BMS deal weighs on Celgene partners
BMS deal weighs on Celgene partners
BioCentury
M&A
Celgene
Bristol-Myers Squibb
Acceleron
BeiGene
Flag link:
Bristol-Myers to buy Celgene in industry-shaking $74B deal
Bristol-Myers to buy Celgene in industry-shaking $74B deal
Biopharma Dive
M&A
Bristol-Myers Squibb
Celgene
immuno-oncology
Flag link:
Celgene invests in Chinese biotech Antengene again
Celgene invests in Chinese biotech Antengene again
Fierce Biotech
Celgene
Antengene
China
Flag link:
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
Down but Not Out: 10 Biggest Drug Trials That Saw Challenges in 2018
BioSpace
clinical trials
Takeda
Zinfandel Pharmaceuticals
pioglitazone
Alzheimer's disease
Boehringer Ingelheim
BI 409306
Merck
verubecestat
Celgene
MS
ozanimod
Incyte
ID01
melanoma
vTv Therapeutics
azeliragon
Roche
Tecentriq
Exelixis
colorectal cancer
JNJ
atabacestat
Sareptat Therapeutics
DMD
Exondys 51
Alkermes
ALKS-5461
clinical depression
Flag link:
3 Biotechs With Potential Blockbusters Near the Finish Line
3 Biotechs With Potential Blockbusters Near the Finish Line
Motley Fool
Vertex Pharmaceuticals
VX-659 + tezacaftor + ivacaftor
Celgene
JCAR017
Novo Nordisk
semaglutide
Flag link:
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
15 For ’19: Key Clinical Data To Watch For Next Year (Part 1)
Xconomy
clinical trials
Alzheimer's disease
Biogen
Duchenne Muscular Dystrophy
Pfizer
Solid Biosciences
Sarepta Therapeutics
hemophilia A
Biomarin
Multiple Myeloma
Celgene
Bluebird Bio
Amgen
solid tumors
Bristol-Myers Squibb
Nektar Therapeutics
age-related macular degeneration
Regenxbio
SAGE Therapeutics
MorphoSys
Flag link:
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Multiple Myeloma Research Foundation Bets on Adaptive Platform Clinical Trial Design
Xtalks
clinical trials
Multiple Myeloma
adaptive trial design
AbbVie
Celgene
Eli Lilly
Genentech
Janssen
Takeda
Flag link:
Can Celgene and bluebird bio Survive a Two-Pronged Attack?
Can Celgene and bluebird bio Survive a Two-Pronged Attack?
Motley Fool
Celgene
Bluebird Bio
bb21217
Flag link:
Celgene scores at ASH18 with double luspatercept data
Celgene scores at ASH18 with double luspatercept data
Pharmaforum
Celgene
luspatercept
ASH2018
Flag link:
ASH18: CAR-T shows up in early CLL test
ASH18: CAR-T shows up in early CLL test
Biopharma Dive
Celgene
CAR-T
CLL
ASH2018
JCAR017
Flag link:
Top Biotech Stocks to Watch at ASH 2018
Top Biotech Stocks to Watch at ASH 2018
Yahoo/Motley Fool
ASH2018
Celgene
Bluebird Bio
Acceleron
Flag link:
Roche’s Tecentriq gets fast review in triple negative breast cancer
Roche’s Tecentriq gets fast review in triple negative breast cancer
Pharmaforum
Roche
Genentech
Tecentriq
Celgene
Abraxane
FDA
triple negative breast cancer
Flag link:
Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myeloma
Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myeloma
Fierce Pharma
Bristol-Myers Squibb
AbbVie
Empliciti
FDA
Multiple Myeloma
Celgene
Pomalyst
Flag link:
Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma
Celgene lines up for $600M Revlimid boost as Rituxan combo scores in lymphoma
Fierce Pharma
Celgene
Revlimid
Roche
Rituxan
follicular lymphoma
Flag link:
Celgene to launch five new products through to 2020
Celgene to launch five new products through to 2020
PM Live
Celgene
Revlimid
FDA
fedratinib
ozanimod
luspatercept
bb2121
liso-cel
Flag link:
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
Up on Deck! Ten Q3 Biotech Earnings Reports to Watch Next Week
BioSpace
earnings
biotech
Biogen
Alexion Pharmaceuticals
Bristol-Myers Squibb
Celgene
Gilead Sciences
Merck
Biomarin
Galapagos
Seattle Genetics
Dr Reddy's
Flag link:
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
CP Wire
Celgene
ozanimod
multiple sclerosis
Flag link:
Celgene Reports Positive Results from New Analyses of Ozanimod in Multiple Sclerosis
Celgene
ozanimod
multiple sclerosis
Flag link:
Celgene notches positive Otezla data in scalp psoriasis as it guns for market expansion
Celgene notches positive Otezla data in scalp psoriasis as it guns for market expansion
Fierce Pharma
Celgene
Otezla
scalp psoriasis
FDA
Flag link:

Pages